论文部分内容阅读
全球糖尿病防治龙头企业诺和诺德(中国)制药有限公司近日宣布,由于中国糖尿病防治市场的迅猛发展和全球业务战略的需要,诺和诺德大中华区将升级为独立大区,直接向丹麦总部汇报。公司还将加大在华投入,在未来3～5年内将其位于北京的研发中心的规模扩大一倍。据介绍,从2011年1月1日起,诺和诺德大中华区将升级为独立大区,
Novo Nordisk (China) Pharmaceutical Co., Ltd., the global leader in diabetes prevention and control, announced recently that due to the rapid development of the Chinese diabetes prevention and control market and the global business strategy, Novo Nordisk Greater China will upgrade to an independent region directly to Denmark Headquarters report. The company will also increase its investment in China and double its R & D center in Beijing within the next 3-5 years. According to reports, from January 1, 2011 onwards, Novo Nordisk Greater China will be upgraded to an independent region,